Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12046663 | 0.91 | PDE10A (0.38) | PDE7APDE3APDE10ACNR2CNR1 | |
| SCHEMBL1160285 | 0.85 | PDE10A (0.36) | PDE7APDE3APDE10ACNR2CNR1 | |
| SCHEMBL1160322 | 0.82 | PDE10A (0.41) | PDE7APDE3APDE10AMEN1KMT2A | |
| SCHEMBL1199331 | 0.80 | PDE10A (0.42) | PDE7APDE3APDE10AMEN1KMT2A | |
| SCHEMBL1198810 | 0.78 | PDE7A (0.41) | PDE7APDE3APDE10ACNR2 | |
| SCHEMBL1199285 | 0.78 | PDE10A (0.41) | PDE7APDE3APDE10ACNR2CNR1 | |
| SCHEMBL12046660 | 0.77 | CNR1 (0.40) | PDE10ACNR2CNR1KMT2A | |
| SCHEMBL30759620 | 0.77 | PDE7A (0.40) | PDE7APDE3APDE10ACNR2CNR1 | |
| SCHEMBL30759622 | 0.77 | PDE7A (0.40) | PDE7APDE3APDE10ACNR2CNR1 | |
| SCHEMBL27119529 | 0.77 | PDE7A (0.40) | PDE7APDE3APDE10ACNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459551-B1 | DIHYDROBENZOINDAZOLES | MERCK SHARP & DOHME (NL) | 2014-07-02 | — | — | EP | disclosed |
| US-8071589-B2 | Dihydrobenzoindazoles | N. V. ORGANON (NL) | 2011-12-06 | — | — | US | disclosed |
| WO-2011012674-A1 | DIHYDROBENZOINDAZOLES | N.V. ORGANON (NL) | 2011-02-03 | — | — | WO | disclosed |
| US-20110028451-A1 | Dihydrobenzoindazoles | N.V. ORGANON (NL) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028451-A1 | Dihydrobenzoindazoles | DHODH, BRDT, HSD17B11 | PDE7A 2158/4885PDE3A 931/4885PDE10A 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.